Jump Financial, LLC Pliant Therapeutics, Inc. Transaction History

Jump Financial, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 21, 2024	SELL	$14.58 - $20.15 $360,738 - $498,551	-24,742 Reduced 23.9%	78,768 $1.37 Million
Q3 2023 Nov 07, 2023	SELL	$14.58 - $20.15 $360,738 - $498,551	-24,742 Reduced 23.9%	78,768 $1.37 Million
Q2 2023 Oct 21, 2024	BUY	$18.12 - $30.56 $682,091 - $1.15 Million	37,643 Added 57.15%	103,510 $1.88 Million
Q2 2023 Aug 07, 2023	BUY	$18.12 - $30.56 $682,091 - $1.15 Million	37,643 Added 57.15%	103,510 $1.88 Million
Q1 2023 Oct 21, 2024	BUY	$18.73 - $36.26 $1.23 Million - $2.39 Million	65,867 New	65,867 $1.75 Million
Q1 2023 May 03, 2023	BUY	$18.73 - $36.26 $430,565 - $833,544	22,988 Added 53.61%	65,867 $1.75 Million
Q4 2022 Feb 13, 2023	SELL	$17.0 - $25.43 $56,474 - $84,478	-3,322 Reduced 7.19%	42,879 $828,000
Q3 2022 Nov 07, 2022	BUY	$7.67 - $24.23 $105,086 - $331,975	13,701 Added 42.16%	46,201 $965,000
Q2 2022 Aug 09, 2022	BUY	$4.11 - $8.75 $81,521 - $173,556	19,835 Added 156.61%	32,500 $260,000
Q1 2022 May 12, 2022	BUY	$7.01 - $14.1 $17,279 - $34,756	2,465 Added 24.17%	12,665 $88,000
Q4 2021 Feb 10, 2022	BUY	$12.27 - $18.26 $125,154 - $186,252	10,200 New	10,200 $138,000

168

63.2M

245K

373K

Ticker PLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,682,000
Market Cap $600M
Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.